ADOCIA a biotechnology company dedicated to protein delivery

  • Contact
  • Linkedin
  • Twitter
  • Youtube
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
    • Cell Therapy: AdoShell Islets
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Gender Equality index
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

Press Releases 

  • General News
  • Financial News

2023

Download
2023/03/15 ADOCIA announces its annual results for 2022 and provides corporate and financial update Adobe_PDF_Icon.svg
2023/01/30 Adocia publishes its Letter to Shareholders Adobe_PDF_Icon.svg

2022

Download
2022/12/21 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Adobe_PDF_Icon.svg
2022/12/01 Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products Adobe_PDF_Icon.svg
2022/10/25 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Adobe_PDF_Icon.svg
2022/10/06 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Adobe_PDF_Icon.svg
2022/10/03 ADOCIA: Upcoming investor meetings Adobe_PDF_Icon.svg
2022/09/19 ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Adobe_PDF_Icon.svg
2022/09/15 ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th Adobe_PDF_Icon.svg
2022/09/07 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Adobe_PDF_Icon.svg
2022/08/24 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Adobe_PDF_Icon.svg
2022/06/23 Adocia publishes its Letter to Shareholders Adobe_PDF_Icon.svg
2022/06/21 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Adobe_PDF_Icon.svg
2022/06/16 ADOCIA confirms its eligibility for the PEA–PME Adobe_PDF_Icon.svg
2022/05/20 ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris Adobe_PDF_Icon.svg
2022/05/18 ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update Adobe_PDF_Icon.svg
2022/05/18 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2022/05/09 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2022/04/19 ADOCIA announces its annual results for 2021 and presents an update on activities Adobe_PDF_Icon.svg
2022/04/11 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2022/03/28 Adocia strengthens its cash position by 19 million euros following a real estate transaction Adobe_PDF_Icon.svg
2022/02/23 ADOCIA announces 2021 fourth quarter financial results Adobe_PDF_Icon.svg
2022/01/13 ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2022/01/11 Number of shares and voting rights of ADOCIA as of December 31st, 2021 Adobe_PDF_Icon.svg
2022/01/06 ADOCIA announces its financial calendar for 2022 Adobe_PDF_Icon.svg

2021

Download
2021/12/20 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 Adobe_PDF_Icon.svg
2021/12/13 Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides Adobe_PDF_Icon.svg
2021/10/26 Adocia announces 2021 third quarter financial results and a financing of €7 million Adobe_PDF_Icon.svg
2021/10/14 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Adobe_PDF_Icon.svg
2021/09/21 ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD Adobe_PDF_Icon.svg
2021/09/10 Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Adobe_PDF_Icon.svg
2021/09/07 ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities Adobe_PDF_Icon.svg
2021/08/23 Number of shares and voting rights of ADOCIA as of July 31st, 2021 Adobe_PDF_Icon.svg
2021/07/29 Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2021/07/22 ADOCIA Announces Second Quarter 2021 Financial Results Adobe_PDF_Icon.svg
2021/06/29 ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes Adobe_PDF_Icon.svg
2021/06/15 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions Adobe_PDF_Icon.svg
2021/06/08 ADOCIA confirms its eligibility for the PEA–PME Adobe_PDF_Icon.svg
2021/06/02 ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 Adobe_PDF_Icon.svg
2021/06/01 ADOCIA reinforces its board of directors with the appointment of three new independent members. Adobe_PDF_Icon.svg
2021/05/26 ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps Adobe_PDF_Icon.svg
2021/05/11 ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 Adobe_PDF_Icon.svg
2021/04/21 ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 Adobe_PDF_Icon.svg
2021/04/21 ADOCIA Announces First Quarter 2021 Financial Results Adobe_PDF_Icon.svg
2021/03/18 ADOCIA Announces Financial Results 2020 And Provides Corporate Update. Adobe_PDF_Icon.svg
2021/03/10 Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes Adobe_PDF_Icon.svg
2021/01/25 Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2021/01/11 Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes Adobe_PDF_Icon.svg

2020

Download
2020/12/21 Adocia announces its financial calendar for 2021 Adobe_PDF_Icon.svg
2020/10/20 Adocia Announces Third Quarter 2020 Financial Results Adobe_PDF_Icon.svg
2020/09/22 Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 Adobe_PDF_Icon.svg
2020/09/15 Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes. Adobe_PDF_Icon.svg
2020/09/07 September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) Adobe_PDF_Icon.svg
2020/09/03 September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD). Adobe_PDF_Icon.svg
2020/08/18 Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. Adobe_PDF_Icon.svg
2020/07/30 Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S Adobe_PDF_Icon.svg
2020/07/20 Adocia Announces First Half 2020 Financial Results Adobe_PDF_Icon.svg
2020/06/08 Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience Adobe_PDF_Icon.svg
2020/04/23 Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes Adobe_PDF_Icon.svg
2020/04/23 Adocia announces the release of its Universal Reference Document for the year 2019 Adobe_PDF_Icon.svg
2020/04/20 Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon Adobe_PDF_Icon.svg
2020/04/14 Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 Adobe_PDF_Icon.svg
2020/03/12 Adocia Announces Full Year 2019 Financial Results Adobe_PDF_Icon.svg

2019

Download
2019/12/17 Adocia announces its financial calendar for 2020 Adobe_PDF_Icon.svg
2019/12/11 Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners Adobe_PDF_Icon.svg
2019/10/22 Adocia Announces Third Quarter 2019 Financial Results Adobe_PDF_Icon.svg
2019/10/14 Adocia obtains additional financial resources to accelerate its growth Adobe_PDF_Icon.svg
2019/09/30 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case Adobe_PDF_Icon.svg
2019/09/10 Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD Adobe_PDF_Icon.svg
2019/08/23 Adocia announces the decision of the American Arbitration Association Tribunal Adobe_PDF_Icon.svg
2019/07/17 Adocia Presents First Half 2019 Financial Results Adobe_PDF_Icon.svg
2019/06/06 Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes Adobe_PDF_Icon.svg
2019/06/04 Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions Adobe_PDF_Icon.svg
2019/04/15 Adocia announces the release of its Reference Document for the year 2018 Adobe_PDF_Icon.svg
2019/04/15 Adocia announces first quarter 2019 financial results: cash position and revenue Adobe_PDF_Icon.svg
2019/04/10 Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin Adobe_PDF_Icon.svg
2019/04/10 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris Adobe_PDF_Icon.svg
2019/03/13 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position Adobe_PDF_Icon.svg
2019/02/12 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 Adobe_PDF_Icon.svg
2019/01/16 Adocia confirms its financial calendar for 2019 Adobe_PDF_Icon.svg
2019/01/03 PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas Adobe_PDF_Icon.svg

2018

Download
2018/12/20 Adocia announces its financial calendar for 2019 Adobe_PDF_Icon.svg
2018/10/23 Adocia Announces Third Quarter 2018 Financial Results Adobe_PDF_Icon.svg
2018/10/11 Adocia informs about a civil action filed by Eli Lilly Adobe_PDF_Icon.svg
2018/10/05 Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon Adobe_PDF_Icon.svg
2018/09/26 Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) Adobe_PDF_Icon.svg
2018/09/05 Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Adobe_PDF_Icon.svg
2018/08/30 Adocia Announces Update to Second Arbitration Against Eli Lilly & Company Adobe_PDF_Icon.svg
2018/08/21 Number of shares and voting rights of ADOCIA as of July 31, 2018 Adobe_PDF_Icon.svg
2018/08/08 American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly Adobe_PDF_Icon.svg
2018/07/25 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2018/07/18 Adocia Presents First Half 2018 Financial Results Adobe_PDF_Icon.svg
2018/06/14 Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions Adobe_PDF_Icon.svg
2018/06/05 Adocia to Participate in the Jefferies 2018 Global Healthcare Conference Adobe_PDF_Icon.svg
2018/06/01 Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine Adobe_PDF_Icon.svg
2018/05/02 Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao Adobe_PDF_Icon.svg
2018/04/26 Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China. Adobe_PDF_Icon.svg
2018/04/19 Adocia announces the release of its Reference Document for the year 2017 Adobe_PDF_Icon.svg
2018/04/16 Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes Adobe_PDF_Icon.svg
2018/04/16 Adocia announces first quarter 2018 financial results: Cash position and revenue Adobe_PDF_Icon.svg
2018/04/09 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon Adobe_PDF_Icon.svg
2018/03/19 ADOCIA announced its financial results for 2017 and its perspectives for 2018 Adobe_PDF_Icon.svg
2018/02/09 Adocia to Present at the 2018 BIO CEO & Investor Conference in New York Adobe_PDF_Icon.svg
2018/02/06 Adocia Files Additional Arbitration Claims Against Eli Lilly & Company Adobe_PDF_Icon.svg
2018/01/25 Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2018/01/08 Adocia announces its financial calendar for 2018 Adobe_PDF_Icon.svg
2018/01/04 Adocia announces expanded use of BioChaperone® beyond diabetes Adobe_PDF_Icon.svg

2017

Download
2017/12/06 Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes Adobe_PDF_Icon.svg
2017/11/20 Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study Adobe_PDF_Icon.svg
2017/10/11 Adocia announces financial results for the third quarter 2017 Adobe_PDF_Icon.svg
2017/09/05 Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes Adobe_PDF_Icon.svg
2017/07/26 Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer Adobe_PDF_Icon.svg
2017/07/19 Adocia presents first half 2017 financial results Adobe_PDF_Icon.svg
2017/06/07 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2017/06/06 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2017/06/01 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump Adobe_PDF_Icon.svg
2017/06/01 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon Adobe_PDF_Icon.svg
2017/05/30 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions Adobe_PDF_Icon.svg
2017/05/30 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York Adobe_PDF_Icon.svg
2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Adobe_PDF_Icon.svg
2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Adobe_PDF_Icon.svg
2017/04/18 Adocia announces first quarter 2017 financial results Adobe_PDF_Icon.svg
2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 Adobe_PDF_Icon.svg
2017/03/21 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 Adobe_PDF_Icon.svg
2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Adobe_PDF_Icon.svg
2017/02/14 Adocia announces its revenue and cash position for 2016 Adobe_PDF_Icon.svg
2017/02/13 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference Adobe_PDF_Icon.svg
2017/01/27 Adocia to hold conference call on Monday January 30, 2017 Adobe_PDF_Icon.svg
2017/01/27 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro Adobe_PDF_Icon.svg
2017/01/25 Adocia to hold conference call providing an update on its programs Adobe_PDF_Icon.svg
2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects Adobe_PDF_Icon.svg
2017/01/05 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes Adobe_PDF_Icon.svg
2017/01/04 Adocia announces its financial calendar for 2017 Adobe_PDF_Icon.svg

2016

Download
2016/12/16 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro Adobe_PDF_Icon.svg
2016/11/10 Adocia to Participate in Upcoming Investor Conferences Adobe_PDF_Icon.svg
2016/11/07 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes Adobe_PDF_Icon.svg
2016/10/27 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/10/12 Adocia announces third quarter 2016 financial results Adobe_PDF_Icon.svg
2016/09/22 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region Adobe_PDF_Icon.svg
2016/09/20 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/09/19 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) Adobe_PDF_Icon.svg
2016/09/08 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting Adobe_PDF_Icon.svg
2016/09/07 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s Adobe_PDF_Icon.svg
2016/08/25 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer Adobe_PDF_Icon.svg
2016/07/20 Adocia presents first half 2016 financial results Adobe_PDF_Icon.svg
2016/07/05 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2016/06/08 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon Adobe_PDF_Icon.svg
2016/06/06 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions Adobe_PDF_Icon.svg
2016/06/02 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Adobe_PDF_Icon.svg
2016/05/31 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Adobe_PDF_Icon.svg
2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Adobe_PDF_Icon.svg
2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio Adobe_PDF_Icon.svg
2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/04/14 Adocia announces first quarter 2016 results Adobe_PDF_Icon.svg
2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 Adobe_PDF_Icon.svg
2016/03/25 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Adobe_PDF_Icon.svg
2016/03/16 Annual Financial Results 2015 Adobe_PDF_Icon.svg
2016/03/14 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Adobe_PDF_Icon.svg
2016/02/04 Adocia to Present at the 2016 Leerink Global Healthcare Conference Adobe_PDF_Icon.svg
2016/01/29 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Adobe_PDF_Icon.svg
2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2015

Download
2015/12/16 Adocia announces its financial calendar for 2016 Adobe_PDF_Icon.svg
2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Adobe_PDF_Icon.svg
2015/12/11 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 Adobe_PDF_Icon.svg
2015/11/25 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes Adobe_PDF_Icon.svg
2015/11/19 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region Adobe_PDF_Icon.svg
2015/11/04 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results Adobe_PDF_Icon.svg
2015/10/06 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Adobe_PDF_Icon.svg
2015/09/30 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes Adobe_PDF_Icon.svg
2015/08/27 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth Adobe_PDF_Icon.svg
2015/07/10 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo Adobe_PDF_Icon.svg
2015/06/26 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Adobe_PDF_Icon.svg
2015/05/28 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Adobe_PDF_Icon.svg
2015/05/26 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Adobe_PDF_Icon.svg
2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Adobe_PDF_Icon.svg
2015/04/29 Adocia is now integrated into the EnterNext Tech 40 Index Adobe_PDF_Icon.svg
2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Adobe_PDF_Icon.svg
2015/04/14 Adocia announces first quarter 2015 results Adobe_PDF_Icon.svg
2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Adobe_PDF_Icon.svg
2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development Adobe_PDF_Icon.svg
2015/03/05 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly Adobe_PDF_Icon.svg
2015/02/17 ADOCIA: annual revenue and net cash position for 2014 Adobe_PDF_Icon.svg
2015/02/10 Adocia: modification of the means allocated to the liquidity agreement Adobe_PDF_Icon.svg
2015/02/05 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet Adobe_PDF_Icon.svg
2015/01/20 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation Adobe_PDF_Icon.svg
2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2014

Download
2014/12/29 ADOCIA announces its financial calendar for 2015 Adobe_PDF_Icon.svg
2014/12/22 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Adobe_PDF_Icon.svg
2014/12/19 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Adobe_PDF_Icon.svg
2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results Adobe_PDF_Icon.svg
2014/09/30 ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry Adobe_PDF_Icon.svg
2014/09/09 Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes Adobe_PDF_Icon.svg
2014/08/25 Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer Adobe_PDF_Icon.svg
2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 Adobe_PDF_Icon.svg
2014/07/09 Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes Adobe_PDF_Icon.svg
2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) Adobe_PDF_Icon.svg
2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) Adobe_PDF_Icon.svg
2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Adobe_PDF_Icon.svg
2014/06/04 Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 Adobe_PDF_Icon.svg
2014/05/27 Adocia initiates ADR program in the United States Adobe_PDF_Icon.svg
2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a Adobe_PDF_Icon.svg
2014/05/19 Adocia Press Release Liquidity Agreement with Kepler Adobe_PDF_Icon.svg
2014/05/06 Termination of Liquidity Agreement with DSF Markets Adobe_PDF_Icon.svg
2014/04/10 Adocia: Ultra Fast Lispro Clinical Results Adobe_PDF_Icon.svg
2014/04/10 Adocia: Revenue Q1 2014 Adobe_PDF_Icon.svg
2014/03/26 Gerard Soula Interview – La bourse et la vie (Transcript) Adobe_PDF_Icon.svg
2014/03/20 Adocia: Annual results 2013 Adobe_PDF_Icon.svg
2014/03/17 Adocia: confirmation of positive clinical results Combo Adobe_PDF_Icon.svg
2014/02/26 Positive Clinical Results for Combo Adobe_PDF_Icon.svg
2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 Adobe_PDF_Icon.svg
2014/01/28 Adocia strengthens its diabetic foot ulcer patent portfolio Adobe_PDF_Icon.svg
2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 Adobe_PDF_Icon.svg
2014/01/06 Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin Adobe_PDF_Icon.svg

2013

Download
2013/12/09 Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors Adobe_PDF_Icon.svg
2013/11/13 Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog Adobe_PDF_Icon.svg
2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Adobe_PDF_Icon.svg
2013/10/19 Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère Adobe_PDF_Icon.svg
2013/09/05 Activity and results for the first half of 2013 Adobe_PDF_Icon.svg
2013/07/29 Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration Adobe_PDF_Icon.svg
2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance Adobe_PDF_Icon.svg
2013/04/26 Release of 2012 Reference Document (French only) Adobe_PDF_Icon.svg
2013/04/24 Q1 2013 revenues Adobe_PDF_Icon.svg
2013/04/23 Liquidity agreement Adobe_PDF_Icon.svg
2013/04/23 PR Suspension liquidity agreement Adobe_PDF_Icon.svg
2013/03/18 Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency Adobe_PDF_Icon.svg
2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Adobe_PDF_Icon.svg
2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Adobe_PDF_Icon.svg

2012

Download
2012/10/30 Adocia announces the strong growth of its turnover Adobe_PDF_Icon.svg
2012/10/22 Adocia is extending its intellectual property to new formulations of monoclonal antibodies Adobe_PDF_Icon.svg
2012/10/01 EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany Adobe_PDF_Icon.svg
2012/09/12 Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde Adobe_PDF_Icon.svg
2012/09/07 DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India Adobe_PDF_Icon.svg
2012/09/03 Financial results and business report for the first half of 2012 Adobe_PDF_Icon.svg
2012/09/02 WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon Adobe_PDF_Icon.svg
2012/06/13 Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment Adobe_PDF_Icon.svg
2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 Adobe_PDF_Icon.svg
2012/04/23 ADOCIA reports positive phase II clinical results Adobe_PDF_Icon.svg
2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA Adobe_PDF_Icon.svg
2012/03/15 Liquidity agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… Adobe_PDF_Icon.svg

2023

Download
2023/03/17 Number of shares and voting rights of ADOCIA as of February 28th, 2023 Adobe_PDF_Icon.svg
2023/03/15 ADOCIA announces its annual results for 2022 and provides corporate and financial update Adobe_PDF_Icon.svg
2023/02/15 Number of shares and voting rights of ADOCIA as of January 31st, 2023 Adobe_PDF_Icon.svg
2023/01/30 Adocia publishes its Letter to Shareholders Adobe_PDF_Icon.svg
2023/01/23 ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2023/01/16 Number of shares and voting rights of ADOCIA as of December 31st, 2022 Adobe_PDF_Icon.svg
2023/01/12 ADOCIA Announces its financial calendar for 2023 Adobe_PDF_Icon.svg

2022

Download
2022/12/29 ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2022/12/21 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Adobe_PDF_Icon.svg
2022/12/15 Number of shares and voting rights of ADOCIA as of November 30th, 2022 Adobe_PDF_Icon.svg
2022/12/01 Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products Adobe_PDF_Icon.svg
2022/11/16 Number of shares and voting rights of ADOCIA as of October 31st, 2022 Adobe_PDF_Icon.svg
2022/10/25 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Adobe_PDF_Icon.svg
2022/10/13 Number of shares and voting rights of ADOCIA as of September 30th, 2022 Adobe_PDF_Icon.svg
2022/10/06 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Adobe_PDF_Icon.svg
2022/10/03 ADOCIA: Upcoming investor meetings Adobe_PDF_Icon.svg
2022/09/19 ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Adobe_PDF_Icon.svg
2022/09/15 ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th Adobe_PDF_Icon.svg
2022/09/14 Number of shares and voting rights of ADOCIA as of August 31st, 2022 Adobe_PDF_Icon.svg
2022/09/07 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Adobe_PDF_Icon.svg
2022/08/25 Number of shares and voting rights of ADOCIA as of July 31st, 2022 Adobe_PDF_Icon.svg
2022/08/24 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Adobe_PDF_Icon.svg
2022/07/20 Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2022/07/11 Number of shares and voting rights of ADOCIA as of June 30th, 2022 Adobe_PDF_Icon.svg
2022/06/23 Adocia publishes its Letter to Shareholders Adobe_PDF_Icon.svg
2022/06/21 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Adobe_PDF_Icon.svg
2022/06/16 ADOCIA confirms its eligibility for the PEA–PME Adobe_PDF_Icon.svg
2022/06/14 Number of shares and voting rights of ADOCIA as of May 31st, 2022 Adobe_PDF_Icon.svg
2022/05/20 ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris Adobe_PDF_Icon.svg
2022/05/18 ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update Adobe_PDF_Icon.svg
2022/05/18 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2022/05/13 Number of shares and voting rights of ADOCIA as of April 30th, 2022 Adobe_PDF_Icon.svg
2022/05/09 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2022/04/25 ADOCIA Announces the Release of its Universal Registration Document for the Year 2021 Adobe_PDF_Icon.svg
2022/04/19 ADOCIA announces its annual results for 2021 and presents an update on activities Adobe_PDF_Icon.svg
2022/04/15 Number of shares and voting rights of ADOCIA as of March 31st, 2022 Adobe_PDF_Icon.svg
2022/03/28 Adocia strengthens its cash position by 19 million euros following a real estate transaction Adobe_PDF_Icon.svg
2022/03/16 Number of shares and voting rights of ADOCIA as of February 28th, 2022 Adobe_PDF_Icon.svg
2022/02/23 ADOCIA announces 2021 fourth quarter financial results Adobe_PDF_Icon.svg
2022/02/15 Number of shares and voting rights of ADOCIA as of January 31st, 2021 Adobe_PDF_Icon.svg
2022/01/13 ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2022/01/11 Number of shares and voting rights of ADOCIA as of December 31st, 2021 Adobe_PDF_Icon.svg
2022/01/06 ADOCIA announces its financial calendar for 2022 Adobe_PDF_Icon.svg

2021

Download
2021/12/20 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 Adobe_PDF_Icon.svg
2021/12/15 Number of shares and voting rights of ADOCIA as of November 30th, 2021 Adobe_PDF_Icon.svg
2021/11/19 Number of shares and voting rights of ADOCIA as of October 31st, 2021 Adobe_PDF_Icon.svg
2021/10/26 Adocia announces 2021 third quarter financial results and a financing of €7 million Adobe_PDF_Icon.svg
2021/10/14 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Adobe_PDF_Icon.svg
2021/10/12 Number of shares and voting rights of ADOCIA as of September 30th, 2021 Adobe_PDF_Icon.svg
2021/09/13 Number of shares and voting rights of ADOCIA as of August 31st, 2021 Adobe_PDF_Icon.svg
2021/09/10 Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Adobe_PDF_Icon.svg
2021/09/07 ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities Adobe_PDF_Icon.svg
2021/08/23 Number of shares and voting rights of ADOCIA as of July 31st, 2021 Adobe_PDF_Icon.svg
2021/07/29 Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2021/07/22 ADOCIA Announces Second Quarter 2021 Financial Results Adobe_PDF_Icon.svg
2021/07/15 Number of shares and voting rights of ADOCIA as of June 30th, 2021 Adobe_PDF_Icon.svg
2021/06/15 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions Adobe_PDF_Icon.svg
2021/06/10 Number of shares and voting rights of ADOCIA as of May 31st, 2021 Adobe_PDF_Icon.svg
2021/06/08 ADOCIA confirms its eligibility for the PEA–PME Adobe_PDF_Icon.svg
2021/06/01 ADOCIA reinforces its board of directors with the appointment of three new independent members. Adobe_PDF_Icon.svg
2021/05/26 ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps Adobe_PDF_Icon.svg
2021/05/17 Number of shares and voting rights of ADOCIA as of April 30, 2021 Adobe_PDF_Icon.svg
2021/05/11 ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 Adobe_PDF_Icon.svg
2021/04/21 ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 Adobe_PDF_Icon.svg
2021/04/21 ADOCIA Announces First Quarter 2021 Financial Results Adobe_PDF_Icon.svg
2021/04/19 ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021 Adobe_PDF_Icon.svg
2021/03/18 ADOCIA Announces Financial Results 2020 And Provides Corporate Update. Adobe_PDF_Icon.svg
2021/03/17 Number of shares and voting rights of ADOCIA as of February 28th, 2021 Adobe_PDF_Icon.svg
2021/02/16 Number of shares and voting rights of ADOCIA as of January 31, 2021 Adobe_PDF_Icon.svg
2021/01/25 Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao Adobe_PDF_Icon.svg
2021/01/20 Number of shares and voting rights of ADOCIA as of December 31, 2020 Adobe_PDF_Icon.svg
2021/01/18 Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2020

Download
2020/12/21 Adocia announces its financial calendar for 2021 Adobe_PDF_Icon.svg
2020/12/07 Number of shares and voting rights of ADOCIA as of November 30, 2020 Adobe_PDF_Icon.svg
2020/11/06 Number of shares and voting rights of ADOCIA as of October 31, 2020 Adobe_PDF_Icon.svg
2020/10/20 Adocia Announces Third Quarter 2020 Financial Results Adobe_PDF_Icon.svg
2020/10/09 Number of shares and voting rights of ADOCIA as of September 30, 2020 Adobe_PDF_Icon.svg
2020/09/22 Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 Adobe_PDF_Icon.svg
2020/09/08 Number of shares and voting rights of ADOCIA as of August 31, 2020 Adobe_PDF_Icon.svg
2020/09/07 September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) Adobe_PDF_Icon.svg
2020/08/25 Number of shares and voting rights of ADOCIA as of July 31, 2020 Adobe_PDF_Icon.svg
2020/08/18 Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. Adobe_PDF_Icon.svg
2020/07/20 Adocia Announces First Half 2020 Financial Results Adobe_PDF_Icon.svg
2020/07/10 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2020/07/06 Number of shares and voting rights of ADOCIA as of June 30, 2020 Adobe_PDF_Icon.svg
2020/07/03 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2020/06/05 Number of shares and voting rights of ADOCIA as of May 31, 2020 Adobe_PDF_Icon.svg
2020/05/11 Number of shares and voting rights of ADOCIA as of April 30, 2020 Adobe_PDF_Icon.svg
2020/04/23 Adocia announces the release of its Universal Reference Document for the year 2019 Adobe_PDF_Icon.svg
2020/04/20 Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon Adobe_PDF_Icon.svg
2020/04/14 Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 Adobe_PDF_Icon.svg
2020/04/09 Number of shares and voting rights of ADOCIA as of March 31, 2020 Adobe_PDF_Icon.svg
2020/03/12 Adocia Announces Full Year 2019 Financial Results Adobe_PDF_Icon.svg
2020/03/05 Number of shares and voting rights of ADOCIA as of February 28, 2020 Adobe_PDF_Icon.svg
2020/02/06 Number of shares and voting rights of ADOCIA as of January 31, 2019 Adobe_PDF_Icon.svg
2020/01/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2020/01/07 Number of shares and voting rights of ADOCIA as of December 31, 2019 Adobe_PDF_Icon.svg

2019

Download
2019/12/17 Adocia announces its financial calendar for 2020 Adobe_PDF_Icon.svg
2019/12/11 Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners Adobe_PDF_Icon.svg
2019/12/06 Number of shares and voting rights of ADOCIA as of November 30, 2019 Adobe_PDF_Icon.svg
2019/11/07 Number of shares and voting rights of ADOCIA as of October 31st, 2019 Adobe_PDF_Icon.svg
2019/10/22 Adocia Announces Third Quarter 2019 Financial Results Adobe_PDF_Icon.svg
2019/10/14 Adocia obtains additional financial resources to accelerate its growth Adobe_PDF_Icon.svg
2019/10/04 Number of shares and voting rights of ADOCIA as of September 30, 2019 Adobe_PDF_Icon.svg
2019/09/30 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case Adobe_PDF_Icon.svg
2019/09/09 Number of shares and voting rights of ADOCIA as of August 31, 2019 Adobe_PDF_Icon.svg
2019/08/06 Number of shares and voting rights of ADOCIA as of July 31st 2019 Adobe_PDF_Icon.svg
2019/07/17 Adocia Presents First Half 2019 Financial Results Adobe_PDF_Icon.svg
2019/07/11 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2019/07/05 Number of shares and voting rights of ADOCIA as of June 30, 2019 Adobe_PDF_Icon.svg
2019/06/11 Number of shares and voting rights of ADOCIA as of May 31, 2019 Adobe_PDF_Icon.svg
2019/05/07 Number of shares and voting rights of ADOCIA as of April 30, 2019 Adobe_PDF_Icon.svg
2019/04/15 Adocia announces the release of its Reference Document for the year 2018 Adobe_PDF_Icon.svg
2019/04/15 Adocia announces first quarter 2019 financial results: cash position and revenue Adobe_PDF_Icon.svg
2019/04/10 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris Adobe_PDF_Icon.svg
2019/04/04 Number of shares and voting rights of ADOCIA as of March 31, 2019 Adobe_PDF_Icon.svg
2019/03/13 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position Adobe_PDF_Icon.svg
2019/03/08 Number of shares and voting rights of ADOCIA as of February 28, 2019 Adobe_PDF_Icon.svg
2019/02/12 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 Adobe_PDF_Icon.svg
2019/02/08 Number of shares and voting rights of ADOCIA as of January 31, 2019 Adobe_PDF_Icon.svg
2019/01/16 Adocia confirms its financial calendar for 2019 Adobe_PDF_Icon.svg
2019/01/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2019/01/10 Number of shares and voting rights of ADOCIA as of December 31, 2018 Adobe_PDF_Icon.svg

2018

Download
2018/12/20 Adocia announces its financial calendar for 2019 Adobe_PDF_Icon.svg
2018/12/06 Number of shares and voting rights of ADOCIA as of November 30, 2018 Adobe_PDF_Icon.svg
2018/11/07 Number of shares and voting rights of ADOCIA as of October 31, 2018 Adobe_PDF_Icon.svg
2018/10/23 Adocia Announces Third Quarter 2018 Financial Results Adobe_PDF_Icon.svg
2018/10/05 Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon Adobe_PDF_Icon.svg
2018/10/04 Number of shares and voting rights of ADOCIA as of September 30, 2018 Adobe_PDF_Icon.svg
2018/09/06 Number of shares and voting rights of ADOCIA as of August 31, 2018 Adobe_PDF_Icon.svg
2018/08/21 Number of shares and voting rights of ADOCIA as of July 31, 2018 Adobe_PDF_Icon.svg
2018/07/25 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2018/07/18 Adocia Presents First Half 2018 Financial Results Adobe_PDF_Icon.svg
2018/07/04 Number of shares and voting rights of ADOCIA as of June 30, 2018 Adobe_PDF_Icon.svg
2018/06/08 Number of shares and voting rights of ADOCIA as of May, 31 2018 Adobe_PDF_Icon.svg
2018/05/07 Number of shares and voting rights of ADOCIA as of April, 30 2018 Adobe_PDF_Icon.svg
2018/04/19 Adocia announces the release of its Reference Document for the year 2017 Adobe_PDF_Icon.svg
2018/04/16 Number of shares and voting rights of ADOCIA as of March, 31 2018 Adobe_PDF_Icon.svg
2018/04/16 Adocia announces first quarter 2018 financial results: Cash position and revenue Adobe_PDF_Icon.svg
2018/04/09 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon Adobe_PDF_Icon.svg
2018/03/19 ADOCIA announced its financial results for 2017 and its perspectives for 2018 Adobe_PDF_Icon.svg
2018/03/16 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2018/03/06 Number of shares and voting rights of ADOCIA as of February 28, 2018 Adobe_PDF_Icon.svg
2018/02/12 Number of shares and voting rights of ADOCIA as of January 31, 2018 Adobe_PDF_Icon.svg
2018/02/12 Adocia: additional resources allocated to the liquidity agreement Adobe_PDF_Icon.svg
2018/01/10 Number of shares and voting rights of ADOCIA as of December 31, 2017 Adobe_PDF_Icon.svg
2018/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2018/01/08 Adocia announces its financial calendar for 2018 Adobe_PDF_Icon.svg

2017

Download
2017/12/07 Number of shares and voting rights of ADOCIA as of November 30, 2017 Adobe_PDF_Icon.svg
2017/11/08 Number of shares and voting rights of ADOCIA as of October 31, 2017 Adobe_PDF_Icon.svg
2017/10/12 Number of shares and voting rights of ADOCIA as of September 30, 2017 Adobe_PDF_Icon.svg
2017/10/11 Adocia announces financial results for the third quarter 2017 Adobe_PDF_Icon.svg
2017/09/18 Number of shares and voting rights of ADOCIA as of August 31, 2017 Adobe_PDF_Icon.svg
2017/07/19 Adocia presents first half 2017 financial results Adobe_PDF_Icon.svg
2017/07/11 Number of shares and voting rights of ADOCIA as of June 30, 2017 Adobe_PDF_Icon.svg
2017/07/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2017/06/09 Number of shares and voting rights of ADOCIA as of May 31, 2017 Adobe_PDF_Icon.svg
2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Adobe_PDF_Icon.svg
2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Adobe_PDF_Icon.svg
2017/04/18 Adocia announces first quarter 2017 financial results Adobe_PDF_Icon.svg
2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 Adobe_PDF_Icon.svg
2017/03/21 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 Adobe_PDF_Icon.svg
2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Adobe_PDF_Icon.svg
2017/02/14 Adocia announces its revenue and cash position for 2016 Adobe_PDF_Icon.svg
2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects Adobe_PDF_Icon.svg
2017/01/06 Half year report on Adocia’s liquidity agreement with Kepler Chevreux Adobe_PDF_Icon.svg
2017/01/04 Adocia announces its financial calendar for 2017 Adobe_PDF_Icon.svg

2016

Download
2016/10/12 Adocia announces third quarter 2016 financial results Adobe_PDF_Icon.svg
2016/07/20 Adocia presents first half 2016 financial results Adobe_PDF_Icon.svg
2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Adobe_PDF_Icon.svg
2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio Adobe_PDF_Icon.svg
2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/04/14 Adocia announces first quarter 2016 results Adobe_PDF_Icon.svg
2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 Adobe_PDF_Icon.svg
2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Adobe_PDF_Icon.svg
2016/03/16 Annual Financial Results 2015 Adobe_PDF_Icon.svg
2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Adobe_PDF_Icon.svg
2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2015

Download
2015/12/16 Adocia announces its financial calendar for 2016 Adobe_PDF_Icon.svg
2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Adobe_PDF_Icon.svg
2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results Adobe_PDF_Icon.svg
2015/10/06 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Adobe_PDF_Icon.svg
2015/10/05 Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon Adobe_PDF_Icon.svg
2015/09/17 ADOCIA: additional contribution to the liquidity agreement Adobe_PDF_Icon.svg
2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth Adobe_PDF_Icon.svg
2015/07/07 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Adobe_PDF_Icon.svg
2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Adobe_PDF_Icon.svg
2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Adobe_PDF_Icon.svg
2015/04/14 Adocia announces first quarter 2015 results Adobe_PDF_Icon.svg
2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Adobe_PDF_Icon.svg
2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development Adobe_PDF_Icon.svg
2015/02/17 ADOCIA: annual revenue and net cash position for 2014 Adobe_PDF_Icon.svg
2015/02/10 Adocia: modification of the means allocated to the liquidity agreement Adobe_PDF_Icon.svg
2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2014

Download
2014/12/29 ADOCIA announces its financial calendar for 2015 Adobe_PDF_Icon.svg
2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results Adobe_PDF_Icon.svg
2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 Adobe_PDF_Icon.svg
2014/07/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) Adobe_PDF_Icon.svg
2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) Adobe_PDF_Icon.svg
2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Adobe_PDF_Icon.svg
2014/05/27 Adocia initiates ADR program in the United States Adobe_PDF_Icon.svg
2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a Adobe_PDF_Icon.svg
2014/05/19 Adocia Press Release Liquidity Agreement with Kepler Adobe_PDF_Icon.svg
2014/05/06 Termination of Liquidity Agreement with DSF Markets Adobe_PDF_Icon.svg
2014/04/10 Adocia: Revenue Q1 2014 Adobe_PDF_Icon.svg
2014/03/20 Adocia: Annual results 2013 Adobe_PDF_Icon.svg
2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 Adobe_PDF_Icon.svg
2014/01/29 2014 Financial Calendar Adobe_PDF_Icon.svg
2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 Adobe_PDF_Icon.svg

2013

Download
2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Adobe_PDF_Icon.svg
2013/09/05 Activity and results for the first half of 2013 Adobe_PDF_Icon.svg
2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance Adobe_PDF_Icon.svg
2013/04/26 Release of 2012 Reference Document (French only) Adobe_PDF_Icon.svg
2013/04/24 Q1 2013 revenues Adobe_PDF_Icon.svg
2013/04/23 Liquidity agreement Adobe_PDF_Icon.svg
2013/04/23 PR Suspension liquidity agreement Adobe_PDF_Icon.svg
2013/03/20 2012 Annual Results Adobe_PDF_Icon.svg
2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Adobe_PDF_Icon.svg
2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Adobe_PDF_Icon.svg

2012

Download
2012/10/30 Adocia announces the strong growth of its turnover Adobe_PDF_Icon.svg
2012/09/24 Large & Midcap Event – 24-25 September 2012, Paris Adobe_PDF_Icon.svg
2012/09/04 SFAF meeting – Half year 2012 results. At 14:30, NYSE EURONEXT, room Auditorium – 3 rue Cambon – 75001 Paris Adobe_PDF_Icon.svg
2012/09/03 Financial results and business report for the first half of 2012 Adobe_PDF_Icon.svg
2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 Adobe_PDF_Icon.svg
2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA Adobe_PDF_Icon.svg
2012/03/15 Liquidity agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… Adobe_PDF_Icon.svg

News

  • Press Releases
  • Upcoming Events

A la Une / Spotlight

  • 100 years ago, the first insulin injection saved Leonard Thompson

    This week, it has been 100 years since 14-year-...
  • Upcoming Investor Conferences – January 2022

    Dear investors, Adocia invites you to meet mana...

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP